Novonesis (novozymes)-ADRNVZMY
13F holders, Q1 2024 (March 31)9holders
$58.66avg. 13F price*
At the end of Q1 2024, 9 institutions reported holding Novonesis (novozymes)-ADR (NVZMY) in their 13F filings. The largest holders were Rhumbline Advisers ($489K), Boston Common Asset Management, LLC ($314K) and Mar Vista Investment Partners LLC ($267K).
- Company
- Novonesis (novozymes)-ADR
- CUSIP
- 670108109
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $3.4M |
Ownership 9 holders
| Rhumbline Advisers | 0.00% | Add +230.6% | 8,307 | $489K |
| Boston Common Asset Management, LLC | 0.01% | Reduce -2.0% | 5,354 | $314K |
| Mar Vista Investment Partners LLC | 0.01% | Add +1490.2% | 4,532 | $267K |
| S&co Inc. | 0.02% | No change | 4,500 | $264K |
| PNC Financial Services Group, Inc. | 0.00% | Reduce -6.6% | 2,249 | $132K |
| Wetzel Investment Advisors, Inc. | 0.02% | Reduce -24.2% | 769 | $42K |
| GAMMA Investing LLC | 0.01% | Add +45.1% | 692 | $41K |
| Operose Advisors LLC | 0.00% | No change | 102 | $6K |
| Financial Avengers, Inc. | 0.00% | No change | 10 | $583 |
"% of holder's portfolio" is NVZMY's weight in each manager's 13F, not the share of Novonesis (novozymes)-ADR the manager owns.